{
  "schema": "http://google-preview.miscsubjects.com/schemas/jarticle.json",
  "status": "published",
  "slug": "semaglutide-metformin",
  "title": "semaglutide metformin",
  "kind": "standard",
  "summary": "Evidence is being populated by Grok web",
  "created": "2026-06-29T17:31:34.058Z",
  "body": [
    "## Overview\nEvidence is being populated by Grok web search."
  ],
  "facts": {
    "converted_from": "markdown",
    "original_updated": "2026-06-29T17:32:34.856Z",
    "register": "standard",
    "category": null
  },
  "sources": [
    {
      "id": "s1",
      "type": "pubmed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/39700591/",
      "title": "The effect of semaglutide combined with metformin on liver inflammation and pancreatic beta-cell function in patients with type 2 diabetes and non-alcoholic fatty liver disease",
      "quote": "The combination of semaglutide and metformin significantly improves liver inflammation, fibrosis, and beta-cell function in patients with T2DM and NAFLD",
      "summary": "2025 study on benefits of semaglutide + metformin combo for liver inflammation, fibrosis, and beta-cell function in T2DM with NAFLD.",
      "author": "",
      "publisher": "",
      "date": "",
      "claim_ids": [],
      "found_by": "grok-4.3",
      "extra": {},
      "accessed_at": "2026-06-29T17:31:34.180Z",
      "link_status": "ok",
      "quote_status": "verified",
      "prev": "genesis",
      "hash": "939c1ba518ca0aacc5a303cfb560db00ed2189d3a2eabc6c9ad908f7ee46a528",
      "quote_sha256": "c5445ae4e12ac3d6ab344a97944e47e8e9991a0875a3a1a60e14d099a0ca98d8"
    },
    {
      "id": "s2",
      "type": "pubmed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40713699/",
      "title": "Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight/obese women with polycystic ovary syndrome: a prospective, randomized, controlled, open-label clinical trial",
      "quote": "Compared to MET monotherapy, combination therapy with semaglutide and MET significantly reduced body weight, improved insulin resistance, decreased ...",
      "summary": "2025 RCT showing semaglutide + metformin superior to metformin alone for weight, insulin resistance, and reproductive outcomes in PCOS.",
      "author": "",
      "publisher": "",
      "date": "",
      "claim_ids": [],
      "found_by": "grok-4.3",
      "extra": {},
      "accessed_at": "2026-06-29T17:31:34.180Z",
      "link_status": "ok",
      "quote_status": "unverified",
      "prev": "939c1ba518ca0aacc5a303cfb560db00ed2189d3a2eabc6c9ad908f7ee46a528",
      "hash": "a5730eab2acedbf01543c049a95129ca5c5c9e48ac94177f905e1ef844d39969",
      "quote_sha256": "a13cdddab60db8d29f71516b5eef9cf8196dc2c9560ad07a2140c1daf4b5fbe9"
    },
    {
      "id": "s3",
      "type": "pubmed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/39796271/",
      "title": "Single and Combined Impact of Semaglutide, Tirzepatide, and Metformin on β-Cell Maintenance and Function Under High-Glucose-High-Lipid Conditions: A Comparative Study",
      "quote": "The results indicate that combining 1 mM metformin with either 10 nM semaglutide or 10 nM tirzepatide significantly enhances the effects of 10 nM semaglutide",
      "summary": "2025 in vitro study on enhanced effects of semaglutide + metformin combo on beta-cell function under stress.",
      "author": "",
      "publisher": "",
      "date": "",
      "claim_ids": [],
      "found_by": "grok-4.3",
      "extra": {},
      "accessed_at": "2026-06-29T17:31:34.180Z",
      "link_status": "ok",
      "quote_status": "verified",
      "prev": "a5730eab2acedbf01543c049a95129ca5c5c9e48ac94177f905e1ef844d39969",
      "hash": "3f0978346b3c23bfcfcbd50125951f64c3bfdfb540f240392532a44d0096b6f5",
      "quote_sha256": "1e2507774451c57ba5d32997a05badde652e0472e1836fa15ba4e4d305842655"
    },
    {
      "id": "s4",
      "type": "pubmed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42026662/",
      "title": "Efficacy and safety of semaglutide injection in Indian patients with type 2 diabetes mellitus inadequately controlled on metformin: a phase 3, randomized, active-controlled trial (SIZE-DM study)",
      "quote": "Generic semaglutide demonstrated non-inferior efficacy and comparable safety to innovator Semaglutide in Indian adults with T2DM inadequately controlled on metformin",
      "summary": "2026 phase 3 trial of semaglutide add-on to metformin in Indian T2DM patients showing non-inferiority.",
      "author": "",
      "publisher": "",
      "date": "",
      "claim_ids": [],
      "found_by": "grok-4.3",
      "extra": {},
      "accessed_at": "2026-06-29T17:31:34.180Z",
      "link_status": "ok",
      "quote_status": "verified",
      "prev": "3f0978346b3c23bfcfcbd50125951f64c3bfdfb540f240392532a44d0096b6f5",
      "hash": "e4ab26a846164f90d040c14753a80f9834a4e7b7f4687d5aee52cfdec78592b1",
      "quote_sha256": "ff542986315bd3edde9bee9925d07ba0e2e0d1a6c48a6d464a4f0606ab9ec3f8"
    },
    {
      "id": "s5",
      "type": "pubmed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41421448/",
      "title": "Effect of semaglutide with metformin for weight loss and ...",
      "quote": "In this study , we demonstrated a significant efficacy of combined treatment with subcutaneous semaglutide and metformin in effective weight reduction and ...",
      "summary": "Demonstrates significant efficacy of combined subcutaneous semaglutide and metformin for weight reduction.",
      "author": "",
      "publisher": "",
      "date": "",
      "claim_ids": [],
      "found_by": "grok-4.3",
      "extra": {},
      "accessed_at": "2026-06-29T17:31:52.940Z",
      "link_status": "ok",
      "quote_status": "unverified",
      "prev": "e4ab26a846164f90d040c14753a80f9834a4e7b7f4687d5aee52cfdec78592b1",
      "hash": "ac8e4f93cc5d67c878aa5ac170c585f907e44e7d56c6191749bfabbb7ff83e1e",
      "quote_sha256": "4ce68cd85821e29bc707b9c5dfdbaab8933a8ec460840a294f0714b3fb0fd056"
    },
    {
      "id": "s6",
      "type": "pubmed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41893436/",
      "title": "Semaglutide Plus Low-Dose Metformin Combination ...",
      "quote": "At 5 months after initiation of the combination therapy, blood tests showed metabolic improvements, including improvement of prediabetes (0.3- ...",
      "summary": "Reports metabolic improvements including prediabetes resolution with semaglutide plus low-dose metformin combination at 5 months.",
      "author": "",
      "publisher": "",
      "date": "",
      "claim_ids": [],
      "found_by": "grok-4.3",
      "extra": {},
      "accessed_at": "2026-06-29T17:31:52.940Z",
      "link_status": "ok",
      "quote_status": "unverified",
      "prev": "ac8e4f93cc5d67c878aa5ac170c585f907e44e7d56c6191749bfabbb7ff83e1e",
      "hash": "f0a97ce15b9312a5a1b14ff5c1641cc38c5fa34c5eff37c271a8eddb99ab7a66",
      "quote_sha256": "68ae2de162c1b3aa71758e7cb20f2515acc264a40d637d75b14e73ff2f99c2a2"
    },
    {
      "id": "s7",
      "type": "pubmed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40227520/",
      "title": "Semaglutide Plus Metformin Versus ...",
      "quote": "38.7% (12/31) of patients in the monotherapy group achieved the primary outcome of weight loss ≥ 5% from baseline vs. 61.29% (19/31) in the ...",
      "summary": "Compares semaglutide plus metformin vs monotherapy, showing higher rate of ≥5% weight loss in combination group.",
      "author": "",
      "publisher": "",
      "date": "",
      "claim_ids": [],
      "found_by": "grok-4.3",
      "extra": {},
      "accessed_at": "2026-06-29T17:31:52.940Z",
      "link_status": "ok",
      "quote_status": "unverified",
      "prev": "f0a97ce15b9312a5a1b14ff5c1641cc38c5fa34c5eff37c271a8eddb99ab7a66",
      "hash": "32f4801c20eb315f661980715df265ed9468bf6f83abdab1ab048a3ff42dd59e",
      "quote_sha256": "d442d66586ed742da5bf0070b2236ec3be3fe3d03e7304ca963722bacbe1834c"
    },
    {
      "id": "s8",
      "type": "pubmed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41765029/",
      "title": "Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial",
      "quote": "This study aimed to compare the efficacy and safety of orforglipron with oral semaglutide in individuals with type 2 diabetes inadequately controlled with metformin.",
      "summary": "Phase 3 trial comparing orforglipron to oral semaglutide in T2D patients on metformin background; orforglipron showed non-inferiority and superiority in HbA1c reduction.",
      "author": "",
      "publisher": "",
      "date": "",
      "claim_ids": [],
      "found_by": "grok-4.3",
      "extra": {},
      "accessed_at": "2026-06-29T17:32:33.794Z",
      "link_status": "ok",
      "quote_status": "verified",
      "prev": "32f4801c20eb315f661980715df265ed9468bf6f83abdab1ab048a3ff42dd59e",
      "hash": "0e64e41d0b32894c7226e83c200352df0ba4bf86f9f294dbb63b593993d47634",
      "quote_sha256": "2e94ad3c48b932184e5917a4775cd2f32719213f4215a2e4843881d0f70bd278"
    },
    {
      "id": "s9",
      "type": "pubmed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42251859/",
      "title": "Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study",
      "quote": "Participants aged 18 years or older with inadequately controlled type 2 diabetes (HbA1c 7·0-10·5% [53-91 mmol/mol]) receiving metformin with or without an SGLT2 inhibitor, and a BMI of 25 kg/m 2 or more",
      "summary": "CagriSema (cagrilintide + semaglutide) superior to semaglutide alone for HbA1c reduction in T2D patients on metformin ± SGLT2i.",
      "author": "",
      "publisher": "",
      "date": "",
      "claim_ids": [],
      "found_by": "grok-4.3",
      "extra": {},
      "accessed_at": "2026-06-29T17:32:33.794Z",
      "link_status": "ok",
      "quote_status": "unverified",
      "prev": "0e64e41d0b32894c7226e83c200352df0ba4bf86f9f294dbb63b593993d47634",
      "hash": "741b950d596f7752c8d2effec247b1314ddebfc472f53485549f782e34ef8898",
      "quote_sha256": "e05188cb8b787e502ad4c189bda34d892300dbda77e22ae406e5b3215bdbf9e1"
    },
    {
      "id": "s10",
      "type": "pubmed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42219226/",
      "title": "Semaglutide Injection in Indian Patients With Type 2 Diabetes Inadequately Controlled on Metformin",
      "quote": "... metformin therapy and diet & exercise control were randomised (1:1) to receive subcutaneous injections of Test semaglutide or Reference semaglutide once ...",
      "summary": "Phase 3 trial of generic vs reference semaglutide in Indian T2D patients on metformin; non-inferior efficacy and safety.",
      "author": "",
      "publisher": "",
      "date": "",
      "claim_ids": [],
      "found_by": "grok-4.3",
      "extra": {},
      "accessed_at": "2026-06-29T17:32:33.794Z",
      "link_status": "ok",
      "quote_status": "unverified",
      "prev": "741b950d596f7752c8d2effec247b1314ddebfc472f53485549f782e34ef8898",
      "hash": "2396853afc0308d991d3328abca52a25f51f9e46089d1a9fed9cb562580f742c",
      "quote_sha256": "7ba8cd10f039894d42097870f6360039e5a7bf2336e388942b2ee37f3cff16aa"
    },
    {
      "id": "s11",
      "type": "pubmed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41715123/",
      "title": "Efficacy and safety of anti-prediabetic drugs in patients with prediabetes: a systematic review and network meta-analysis",
      "quote": "2.4 mg of semaglutide SC and 15 mg of tirzepatide were the best option among the included interventions considering favorable glucose and BMI control.",
      "summary": "Network meta-analysis including semaglutide and metformin in prediabetes; semaglutide 2.4mg optimal for weight loss and HbA1c.",
      "author": "",
      "publisher": "",
      "date": "",
      "claim_ids": [],
      "found_by": "grok-4.3",
      "extra": {},
      "accessed_at": "2026-06-29T17:32:33.794Z",
      "link_status": "ok",
      "quote_status": "verified",
      "prev": "2396853afc0308d991d3328abca52a25f51f9e46089d1a9fed9cb562580f742c",
      "hash": "0269fe9329cee434595cf3a572ec66d7f0154ae12524b6220e8c2b305d3afdaa",
      "quote_sha256": "d9d5fcfd891ace855aba5a7f571b65066ca1e42e6a469c8467458f293ca5a0cc"
    }
  ],
  "type": "article",
  "updated": "2026-10-08T11:49:33.889Z",
  "version": 1,
  "hash": "d0028e678d0f7be122ba93a18d8fed3569f293dd0218c52339dd2039f82e9e20",
  "styling": {
    "scope": "shared",
    "how": "no value on the page is set by hand: each comes from this theme, and each theme value becomes the CSS variable named beside it. PATCH http://google-preview.miscsubjects.com/api/jarticles/theme changes them.",
    "widget_style": {
      "what": "every widget may carry style: {…}; these are the only keys it reads",
      "rotate": "degrees, a number",
      "offset_x": "pixels, a number",
      "offset_y": "pixels, a number",
      "pulse": "true to pulse"
    },
    "theme": {
      "color": {
        "page_bg": "#f5f5f7",
        "sheet_bg": "#ffffff",
        "ink": "#1d1d1f",
        "soft": "#424245",
        "muted": "#6e6e73",
        "dim": "#86868b",
        "line": "#d2d2d7",
        "accent": "#0071e3",
        "accent_soft": "rgba(0,113,227,0.08)",
        "link": "#0066cc",
        "selection": "rgba(0,113,227,0.18)",
        "widget_bg": "#f5f5f7",
        "widget_border": "#d2d2d7",
        "card_bg": "#ffffff",
        "code_bg": "#f5f5f7",
        "json_bg": "#161b19",
        "json_ink": "#e6e1d4",
        "json_key": "#7fd3c3",
        "json_string": "#e9c46a",
        "json_number": "#f4a261",
        "json_bool": "#c792ea",
        "json_null": "#928d7e",
        "json_punct": "#6b6759",
        "json_bar": "#0e1512",
        "kind_badge_bg": "#0e6e60",
        "kind_badge_ink": "#ffffff"
      },
      "color_dark": {
        "page_bg": "#000000",
        "sheet_bg": "#1d1d1f",
        "ink": "#f5f5f7",
        "soft": "#d2d2d7",
        "muted": "#a1a1a6",
        "dim": "#86868b",
        "line": "#424245",
        "accent": "#2997ff",
        "accent_soft": "rgba(41,151,255,0.12)",
        "link": "#2997ff",
        "selection": "rgba(41,151,255,0.25)",
        "widget_bg": "#2c2c2e",
        "widget_border": "#424245",
        "card_bg": "#1d1d1f",
        "code_bg": "#2c2c2e",
        "json_bg": "#0a0d0c",
        "json_ink": "#e6e1d4",
        "json_key": "#7fd3c3",
        "json_string": "#e9c46a",
        "json_number": "#f4a261",
        "json_bool": "#c792ea",
        "json_null": "#757062",
        "json_punct": "#5d665f",
        "json_bar": "#060807",
        "kind_badge_bg": "#4fc1ab",
        "kind_badge_ink": "#0b0f0d"
      },
      "font": {
        "display": "-apple-system,BlinkMacSystemFont,\"SF Pro Display\",\"SF Pro Text\",\"Helvetica Neue\",Helvetica,Arial,sans-serif",
        "body": "-apple-system,BlinkMacSystemFont,\"SF Pro Display\",\"SF Pro Text\",\"Helvetica Neue\",Helvetica,Arial,sans-serif",
        "mono": "ui-monospace,SFMono-Regular,\"SF Mono\",Menlo,Consolas,monospace",
        "google_fonts": ""
      },
      "size": {
        "body": "17px",
        "small": "17px",
        "eye": "17px",
        "lead": "17px",
        "h1": "52px",
        "h2": "34px",
        "h3": "22px",
        "byline": "17px",
        "h1_measure": "none",
        "code": "17px",
        "json": "17px",
        "widget_title": "17px"
      },
      "leading": {
        "body": "1.7",
        "head": "1.18",
        "lead": "1.5",
        "json": "1.6"
      },
      "weight": {
        "display": "700",
        "head": "700",
        "body": "400",
        "strong": "700",
        "eye": "700"
      },
      "tracking": {
        "eye": "0.14em",
        "display": "-0.03em",
        "body": "-0.006em",
        "badge": "0.08em"
      },
      "layout": {
        "sheet_width": "1000px",
        "text_width": "880px",
        "gutter": "16px",
        "sheet_padding": "56px 64px 64px",
        "sheet_padding_mobile": "24px 18px 40px",
        "sheet_margin": "28px auto 72px",
        "block_gap": "1.15em",
        "widget_gap": "28px",
        "grid_gap": "14px"
      },
      "border": {
        "sheet": "0px solid",
        "sheet_radius": "30px",
        "widget": "1px solid",
        "widget_radius": "24px",
        "card_radius": "24px",
        "badge_radius": "999px",
        "rule": "1px solid",
        "code_radius": "18px",
        "accent_bar": "3px"
      },
      "shadow": {
        "sheet": "0 1px 1px rgba(0,0,0,.02),0 6px 26px rgba(0,0,0,.05)",
        "widget": "none",
        "card_hover": "0 10px 28px -16px rgba(28,27,23,0.35)"
      },
      "motion": {
        "hover": "160ms ease"
      }
    }
  },
  "page": "http://google-preview.miscsubjects.com/a/semaglutide-metformin",
  "json": "http://google-preview.miscsubjects.com/a/semaglutide-metformin.json",
  "markdown": "http://google-preview.miscsubjects.com/a/semaglutide-metformin.md",
  "theme": "http://google-preview.miscsubjects.com/article-theme.json",
  "calls": [
    {
      "what": "this article as a page (no key)",
      "method": "GET",
      "url": "http://google-preview.miscsubjects.com/a/semaglutide-metformin",
      "headers": {}
    },
    {
      "what": "this article as its object (no key)",
      "method": "GET",
      "url": "http://google-preview.miscsubjects.com/a/semaglutide-metformin.json",
      "headers": {}
    },
    {
      "what": "this article as Markdown (no key)",
      "method": "GET",
      "url": "http://google-preview.miscsubjects.com/a/semaglutide-metformin.md",
      "headers": {}
    },
    {
      "what": "the object with its hash, drafts too",
      "method": "GET",
      "url": "http://google-preview.miscsubjects.com/api/jarticles/semaglutide-metformin",
      "headers": {
        "x-sheets-key": "$(cat /Users/cyrusmassoumi/.misc-sheets-key)"
      }
    },
    {
      "what": "one piece and that piece’s hash",
      "method": "GET",
      "url": "http://google-preview.miscsubjects.com/api/jarticles/semaglutide-metformin/at?path=facts",
      "headers": {
        "x-sheets-key": "$(cat /Users/cyrusmassoumi/.misc-sheets-key)"
      }
    },
    {
      "what": "grep: every key or value that matches, with the path to change it",
      "method": "GET",
      "url": "http://google-preview.miscsubjects.com/api/jarticles/semaglutide-metformin/grep?q=owner",
      "headers": {
        "x-sheets-key": "$(cat /Users/cyrusmassoumi/.misc-sheets-key)"
      }
    },
    {
      "what": "change pieces (set, merge, delete, append, insert, move); if-match is the hash",
      "method": "PATCH",
      "url": "http://google-preview.miscsubjects.com/api/jarticles/semaglutide-metformin",
      "headers": {
        "x-sheets-key": "$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
        "content-type": "application/json",
        "if-match": "<hash from the read>"
      },
      "body": {
        "ops": [
          {
            "op": "set",
            "path": "facts.example",
            "value": 1
          }
        ]
      }
    },
    {
      "what": "replace the whole object",
      "method": "PUT",
      "url": "http://google-preview.miscsubjects.com/api/jarticles/semaglutide-metformin",
      "headers": {
        "x-sheets-key": "$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
        "content-type": "application/json",
        "if-match": "<hash>"
      },
      "body": {
        "slug": "semaglutide-metformin",
        "title": "…"
      }
    },
    {
      "what": "fetch every source, hash what came back and check the quote is in it",
      "method": "POST",
      "url": "http://google-preview.miscsubjects.com/api/jarticles/semaglutide-metformin/verify",
      "headers": {
        "x-sheets-key": "$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
        "content-type": "application/json"
      },
      "body": {}
    },
    {
      "what": "an Obsidian-style command",
      "method": "POST",
      "url": "http://google-preview.miscsubjects.com/api/jarticles/cli",
      "headers": {
        "x-sheets-key": "$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
        "content-type": "application/json"
      },
      "body": {
        "command": "backlinks",
        "file": "semaglutide-metformin"
      }
    }
  ]
}